BNP Paribas Financial Markets Sells 10,728 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

BNP Paribas Financial Markets reduced its stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 44.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 13,662 shares of the biopharmaceutical company’s stock after selling 10,728 shares during the quarter. BNP Paribas Financial Markets’ holdings in Revance Therapeutics were worth $42,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in RVNC. Natixis bought a new stake in Revance Therapeutics during the fourth quarter worth approximately $31,000. Two Sigma Securities LLC bought a new stake in Revance Therapeutics during the fourth quarter worth approximately $35,000. Alpine Global Management LLC bought a new stake in Revance Therapeutics during the fourth quarter worth approximately $37,000. RPO LLC bought a new stake in Revance Therapeutics during the fourth quarter worth approximately $55,000. Finally, Ameriprise Financial Inc. increased its stake in Revance Therapeutics by 54.1% during the fourth quarter. Ameriprise Financial Inc. now owns 23,706 shares of the biopharmaceutical company’s stock worth $72,000 after acquiring an additional 8,326 shares during the last quarter. 97.70% of the stock is owned by institutional investors.

Revance Therapeutics Stock Performance

RVNC opened at $3.65 on Wednesday. The stock has a market cap of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The stock’s 50 day moving average price is $3.65 and its 200-day moving average price is $3.57. Revance Therapeutics, Inc. has a one year low of $2.30 and a one year high of $6.65.

Wall Street Analyst Weigh In

Separately, Wall Street Zen started coverage on Revance Therapeutics in a research note on Wednesday, May 21st. They set a “hold” rating on the stock. Eight research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.45.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.